Clinical trial
Phase 2 AMG 714 in Rheumatoid Arthritis
NCT00433875 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00433875 |
|---|---|
| Title | Phase 2 AMG 714 in Rheumatoid Arthritis |
| Official title | A Double-Blind, Placebo Controlled, Randomized, Parallel-Group Clinical Trial With Multiple Dose Treatment of Anti-IL 15 Human Monoclonal Antibody (AMG 714) in Patients With Active Rheumatoid Arthritis Who Have Previously Failed One or More Disease Modifying Anti-Rheumatic Drugs |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | AMG 714 |
| Enrollment | 180 |
| Start date | Dec 1, 2002 |
| First posted | Feb 12, 2007 |
| Last update posted | Dec 28, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: